Discontinued — last reported Q4 '25
Other Income & Expense
Other Income (Expense)
Regeneron Pharmaceuticals Other Income (Expense) increased by 15.0% to $188.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 39.9%, from $313.30M to $188.30M. Over 3 years (FY 2022 to FY 2025), Other Income (Expense) shows an upward trend with a 139.8% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryOther
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
Significant fluctuations often relate to changes in interest rates, investment valuations, or currency volatility.
Detailed definition
The net total of income and expenses from non-operating activities, such as interest income, interest expense, and gains...
Peer comparison
Companies with large cash piles often show significant interest income here, while highly levered firms show interest expense.
Metric ID:
other_income_expense_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $405.60M | -$30.60M | -$197.40M | -$146.70M | $286.10M | $177.90M | -$88.70M | $66.40M | -$200.00K | $174.70M | -$50.70M | $558.50M | $313.50M | $0.00 | $313.30M | $439.20M | $736.50M | $163.80M | $188.30M |
| QoQ Change | — | -107.5% | -545.1% | +25.7% | +295.0% | -37.8% | -149.9% | +174.9% | -100.3% | >999% | -129.0% | >999% | -43.9% | -100.0% | — | +40.2% | +67.7% | -77.8% | +15.0% |
| YoY Change | — | — | — | -136.2% | >999% | — | +55.1% | +145.3% | -100.1% | -1.8% | +42.8% | +741.1% | >999% | -100.0% | +717.9% | -21.4% | +134.9% | — | -39.9% |
Range-$197.40M – $736.50M
CAGR-15.7%
Avg YoY Growth>999%
Median YoY Growth+49.0%
Other Income (Expense) at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's other income (expense)?
- Regeneron Pharmaceuticals (REGN) reported other income (expense) of $188.30M in Q1 2026.
- How has Regeneron Pharmaceuticals's other income (expense) changed year-over-year?
- Regeneron Pharmaceuticals's other income (expense) decreased by 39.9% year-over-year, from $313.30M to $188.30M.
- What is the long-term trend for Regeneron Pharmaceuticals's other income (expense)?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's other income (expense) has grown at a 139.8% compound annual growth rate (CAGR), from $119.90M to $1.65B.
- What does other income (expense) mean?
- Money made or lost from activities not related to the company's main business, like investments or interest.